Research
BioESMART- IGF-1R/HER3 the new AcSé-ESMART treatment arm
BioESMART- IGF-1R/HER3 the new AcSé-ESMART treatment arm
New AcSé-ESMART treatment arm: Testing a novel bispecific antibody targeting IGF-R1 & HER3 in Ewing’s sarcoma and other pediatric cancers Childhood Sarcomas Ewing sarcoma is the second most common malignant bone tumor after osteosarcoma among adolescents and young adults. Ewing sarcoma affects approximately 80 to 100 new patients per year in France. The majority of […]What is a sarcoma?
What is a sarcoma?
Sarcomas are malignant tumors that develop from the body’s supporting tissues or “soft tissues” such as muscles, adipose tissue, cartilage, blood vessels or lymphatics, nerves, or bones. The type of sarcoma depends on the type of cells from which it originated. Sarcomas can be classified into three major categories: Soft tissue sarcomas Visceral sarcomas Bone […]ENCOURAGER: A STUDY AGAINST PEDIATRIC GLIOMAS
ENCOURAGER: A STUDY AGAINST PEDIATRIC GLIOMAS
“Encourager” is a project to explore the cellular origins of therapeutic failure in pediatric gliomas, in order to optimize targeted therapies. Children’s Brain Cancers Brain tumors are the most common solid tumors in children. The annual number of new cases for all children’s brain tumors is estimated at approximately 30 per million. Gliomas encompass tumors […]What is a Glioma?
What is a Glioma?
Brain tumors are the most common solid tumors in pediatrics. The number of new annual cases is estimated at about 30 cases per million. There are several types of brain tumors depending on the cell from which the tumor originates. Gliomas thus come from cells that support neurons, namely astrocytes or oligodendrocytes. These tumors, very […]Molecular Analysis and Testing of New Treatments for Diffuse Midline Gliomas
Molecular Analysis and Testing of New Treatments for Diffuse Midline Gliomas
Diffuse Midline Gliomas in Children Pediatric brain tumors are the leading cause of cancer-related mortality in children. Diffuse midline gliomas are the most common and severe form of malignant gliomas in children and adolescents (between 50 and 100 new cases are expected each year in France). Most affected children die within two years of diagnosis. […]SACHA: the program that secures access to medicines outside clinical trials
SACHA: the program that secures access to medicines outside clinical trials
Context of the SACHA Study France stands as a pioneer in Europe in the field of developing new drugs in pediatric oncology. For example, from 2015 to 2018, over 2,200 patients were enrolled in 34 clinical trials by ITCC (Innovative Therapies for Children with Cancer). Among them, 53% of the patients were recruited in France. […]FIGHT KIDS CANCER 2024 LAUNCHES A CALL FOR EUROPEAN PROJECTS DEDICATED TO BRAIN TUMORS
FIGHT KIDS CANCER 2024 LAUNCHES A CALL FOR EUROPEAN PROJECTS DEDICATED TO BRAIN TUMORS
On the occasion of September in GOLD, Fight Kids Cancer, an initiative created by Imagine for Margo and its European partners, is launching a new call for projects to boost research against childhood brain tumors Brain tumors represent the second most common form of childhood cancer after leukemia. Among solid tumors in children, those of […]SACHA: Accelerate children’s access to innovative molecules – Interview with Dr. Pablo Berlanga
